The Expression of Tumor-Associated Macrophages in Papillary Thyroid Carcinoma

Bo Hyun Kim

doi:10.3803/EnM.2013.28.3.178

Articles

Page Path: HOME > Endocrinol Metab > Volume 28(3); 2013 > Article

Editorial The Expression of Tumor-Associated Macrophages in Papillary Thyroid Carcinoma: Bo Hyun Kim; Endocrinology and Metabolism 2013;28(3):178-179.
DOI: https://doi.org/10.3803/EnM.2013.28.3.178
Published online: September 13, 2013

Department of Internal Medicine and Biomedical Research Institute, Pusan National University School of Medicine, Busan, Korea.

Corresponding author: Bo Hyun Kim. Department of Internal Medicine and Biomedical Research Institute, Pusan National University School of Medicine, 179 Gudeok-ro, Seo-gu, Busan 602-739, Korea. Tel: +82-51-240-7678, Fax: +82-51-254-3237, pons71@hanmail.net

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

3,455 Views
31 Download
11 Crossref

prev next

Full Article

Download PDF

Article information
References

Solid tumors contain not only malignant cells, but also extracellular matrix and many other nonmalignant cells including fibroblasts, endothelial cells, and inflammatory cells such as macrophages, neutrophils, and lymphocytes. The presence of inflammatory cells within solid tumors suggests that the inflammatory microenvironment could play a major role in promoting tumorigenesis and progression. Macrophage infiltrates in the context of or surrounding a variety of malignancies represent the host's immune response to the tumor [1,2].

It was recently reported that tumor-associated macrophages (TAMs) had important roles in the tumor progression and metastasis of various cancers, including advanced thyroid cancer [3-9]. However, the role of TAMs in papillary thyroid carcinoma (PTC) has not been fully elucidated. Fiumara et al. [10] studied the tissue distribution and prognostic significance of TAMs in a retrospective series of 121 PTCs. They found tumor-infiltrating macrophages in approximately 70% of cases. Phagocytosis of neoplastic cells by macrophages was observed in approximately 15% of tumors, and none of these tumors developed distant metastases. These data suggest that neoplastic cell phagocytosis by macrophages and lymphocytic infiltration play a protective role in the development of distant metastases in patients with PTC.

Conversely, emerging data suggest that TAMs promote tumor progression and metastasis in PTC. Ryder et al. [8] reported that an increased density of TAMs was associated with tumor progression in advanced thyroid cancers and that there was a significant correlation between increased TAMs and histological grade, tumor invasiveness, and decreased cancerrelated survival in PTC. Very recently, they also reported that TAMs promoted PTC progression in BRAF-induced PTC mouse models, and that targeting CCR2-expressing cells during BRAF induction reduced TAM density and impaired PTC development [11]. These results suggested that therapeutic strategies targeting TAMs may be beneficial in the treatment of advanced PTC.

Qing et al. [9] investigated TAMs density in both benign thyroid lesions and PTC tumors by CD68 immunostaining. They found that the overall density of TAMs was significantly higher in PTC tumors compared with thyroid goiter and follicular adenoma. In addition, the density of TAMs was positively associated with lymph node (LN) metastasis in TNM stages III/VI compared with stages I/II. However, no association was observed with other common tumor features, including BRAF mutation.

In this issue, Kim et al. [12] investigated the expression of TAMs in 36 PTC patients with LN metastasis using immunohistochemical staining with anti-CD68 antibody. They reported that a higher density of TAMs was correlated with larger tumor size, suggesting a protumorigenic role of TAMs in PTCs. Comparing clinicopathologic characteristics among low (<25%) and high (25% to 70%) TAM density groups, primary tumor size was larger in the high density group compared to the low density group (2.0±0.1 vs. 1.5±0.1; P=0.009). However, there was no significant association between high TAM density and poorer clinicopathologic characteristics including multifocality, LN metastasis, and extrathyroidal extension. These data were not in agreement with those of previous studies, which reported that high TAM density was correlated with tumor invasiveness and poor clinicopathologic characteristics, excepting tumor size [8,9,11].

Kim et al. [12] also analyzed the morphological characteristics of TAMs in PTC. They found that TAMs had thin, elongated cytoplasmic extensions, forming a canopy structure over tumor cells, and that the morphological characteristics of thyroid cancer tissue were well maintained irrespective of the presence of TAMs. In view of this, they inferred that TAMs do not play key role in tumor development in PTC. However, Caillou et al. [13] reported that anaplastic thyroid cancer displayed a very dense network of interconnected ramified TAMs in direct contact with intermingled cancer cells, and that this TAM network was directly related to the aggressiveness of thyroid cancer.

Unfortunately, Kim et al. [12] conducted this study using anti-CD68 antibody on only a small sample of PTCs with LN metastasis. A major limitation of this study was the lack of follow-up data with which to evaluate long-term outcomes. Therefore, further studies using a more specific antibody and larger sample sizes of various stages of PTC are warranted to investigate the role of TAMs in tumor development, tumor invasiveness, and metastasis of PTC. Finally, TAM-targeted pharmacologic therapy in patients with advanced thyroid cancer should also be investigated.

Article information

No potential conflict of interest relevant to this article was reported.

References

1. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539–545. Article PubMed
2. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860–867. Article PubMed PMC PDF
3. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002;196:254–265. Article PubMed
4. Heusinkveld M, van der Burg SH. Identification and manipulation of tumor associated macrophages in human cancers. J Transl Med 2011;9:216Article PubMed PMC PDF
5. Tsutsui S, Yasuda K, Suzuki K, Tahara K, Higashi H, Era S. Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density. Oncol Rep 2005;14:425–431. Article PubMed
6. Hirayama S, Ishii G, Nagai K, Ono S, Kojima M, Yamauchi C, Aokage K, Hishida T, Yoshida J, Suzuki K, Ochiai A. Prognostic impact of CD204-positive macrophages in lung squamous cell carcinoma: possible contribution of Cd204-positive macrophages to the tumor-promoting microenvironment. J Thorac Oncol 2012;7:1790–1797. Article PubMed
7. Takayama H, Nishimura K, Tsujimura A, Nakai Y, Nakayama M, Aozasa K, Okuyama A, Nonomura N. Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guerin instillation. J Urol 2009;181:1894–1900. Article PubMed
8. Ryder M, Ghossein RA, Ricarte-Filho JC, Knauf JA, Fagin JA. Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr Relat Cancer 2008;15:1069–1074. Article PubMed PMC
9. Qing W, Fang WY, Ye L, Shen LY, Zhang XF, Fei XC, Chen X, Wang WQ, Li XY, Xiao JC, Ning G. Density of tumorassociated macrophages correlates with lymph node metastasis in papillary thyroid carcinoma. Thyroid 2012;22:905–910. Article PubMed PMC
10. Fiumara A, Belfiore A, Russo G, Salomone E, Santonocito GM, Ippolito O, Vigneri R, Gangemi P. In situ evidence of neoplastic cell phagocytosis by macrophages in papillary thyroid cancer. J Clin Endocrinol Metab 1997;82:1615–1620. Article PubMed
11. Ryder M, Gild M, Hohl TM, Pamer E, Knauf J, Ghossein R, Joyce JA, Fagin JA. Genetic and pharmacological targeting of CSF-1/CSF-1R inhibits tumor-associated macrophages and impairs BRAF-induced thyroid cancer progression. PLoS One 2013;8:e54302Article PubMed PMC
12. Kim S, Cho SW, Min HS, Kim KM, Yeom GJ, Kim EY, Lee KE, Yun YG, Park DJ, Park YJ. The expression of tumor-associated macrophages in papillary thyroid carcinoma. Endocrinol Metab 2013;28:192–198.Article
13. Caillou B, Talbot M, Weyemi U, Pioche-Durieu C, Al Ghuzlan A, Bidart JM, Chouaib S, Schlumberger M, Dupuy C. Tumor-associated macrophages (TAMs) form an interconnected cellular supportive network in anaplastic thyroid carcinoma. PLoS One 2011;6:e22567Article PubMed PMC

Figure & Data

References

Citations

Citations to this article as recorded by

Circulating immunophenotypes are potentially prognostic in follicular cell-derived thyroid cancer
Anupam Kotwal, Michael P. Gustafson, Svetlana Bornschlegl, Allan B. Dietz, Danae Delivanis, Mabel Ryder
Frontiers in Immunology.2024;[Epub] CrossRef
Clinicopathological Features and Molecular Signatures of Lateral Neck Lymph Node Metastasis in Papillary Thyroid Microcarcinoma
Jinsun Lim, Han Sai Lee, Jin-Hyung Heo, Young Shin Song
Endocrinology and Metabolism.2024; 39(2): 324. CrossRef
Relaxin-2 is a novel biomarker for differentiated thyroid carcinoma in humans
Anupam Kotwal, Ronda Simpson, Nicholas Whiteman, Benjamin Swanson, Ana Yuil-Valdes, Madelyn Fitch, Joshua Nguyen, Salma Elhag, Oleg Shats, Whitney Goldner, Robert Bennett
Biochemical Pharmacology.2024; 225: 116323. CrossRef
Characterization of Immune Infiltrate Along the Leading Edge of Differentiated Thyroid Cancer
Anupam Kotwal, Krysten Vance, Kemal Hajric, Ana Yuil-Valdes, Benjamin Swanson, Ernesto Martinez Duarte, Oleg Shats, Michael Hollingsworth, Hamid Band, Whitney Goldner
Thyroid®.2024;[Epub] CrossRef
Agrin is a novel oncogenic protein in thyroid cancer
Anna Adamiok‑Ostrowska, Małgorzata Grzanka, Barbara Czarnocka
Oncology Letters.2023;[Epub] CrossRef
Comprehensive Analysis of the Prognosis and Drug Sensitivity of Differentiation-Related lncRNAs in Papillary Thyroid Cancer
Wenlong Wang, Ning Bai, Xinying Li
Cancers.2022; 14(5): 1353. CrossRef
GATA binding protein 1 recruits histone deacetylase 2 to the promoter region of nuclear receptor binding protein 2 to affect the tumor microenvironment and malignancy of thyroid carcinoma
Mengyuan Li, Hongwei Jiang, Shengjiang Chen, Yujin Ma
Bioengineered.2022; 13(4): 11336. CrossRef
CLEC3B as a Potential Prognostic Biomarker in Hepatocellular Carcinoma
Xing-Wei Xie, Shan-Shan Jiang, Xiang Li
Frontiers in Molecular Biosciences.2021;[Epub] CrossRef
IL-34 and CSF-1, deciphering similarities and differences at steady state and in diseases
Antoine Freuchet, Apolline Salama, Séverine Remy, Carole Guillonneau, Ignacio Anegon
Journal of Leukocyte Biology.2021; 110(4): 771. CrossRef
Development and validation of a three-immune-related gene signature prognostic risk model in papillary thyroid carcinoma
X. Gan, M. Guo, Z. Chen, Y. Li, F. Shen, J. Feng, W. Cai, B. Xu
Journal of Endocrinological Investigation.2021; 44(10): 2153. CrossRef
Papillary thyroid carcinoma behavior: clues in the tumor microenvironment
Kensey Bergdorf, Donna C Ferguson, Mitra Mehrad, Kim Ely, Thomas Stricker, Vivian L Weiss
Endocrine-Related Cancer.2019; 26(6): 601. CrossRef

PubReader
Cite

CITE

export Copy Format

Close

XML Download

The Expression of Tumor-Associated Macrophages in Papillary Thyroid Carcinoma